We are live on !
Find out more
RS
R Squared Portfolio holdings
AUM
$190M
Turnover
64%
1-Year Est. Return
25.89%
This Fund
S&P 500
This Quarter Est. Return
+15.51%
1 Year Est. Return
+25.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$190M
AUM Growth
+$8.35M
(+4.6%)
Cap. Flow
-$4.65M
Cap. Flow % of AUM
Cap. Flow %
-2.44%
Top 10 Holdings %
Top 10 Hldgs %
14.08%
Holding
725
New
248
Increased
120
Reduced
140
Closed
216
Avg Time Held
0.3
years
Top 10 Avg Time Held
0.2
years
Top 20 Avg Time Held
0.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.3M |
| 2 |
Penumbra
PEN
|
+$2.89M |
| 3 |
Intuitive Surgical
ISRG
|
+$1.9M |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.71M |
| 5 |
Costco
COST
|
+$1.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hologic
HOLX
|
+$5.96M |
| 2 |
Apple
AAPL
|
+$3.04M |
| 3 |
Micron Technology
MU
|
+$2.56M |
| 4 |
Eli Lilly
LLY
|
+$2.13M |
| 5 |
Visa
V
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.35% |
| 2 | Technology | 17.3% |
| 3 | Industrials | 15.96% |
| 4 | Healthcare | 11.59% |
| 5 | Consumer Discretionary | 9.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
451
AirSculpt Technologies
AIRS
$89.8M
| $49K | 0.03% |
+10,895
| New | +$44.2K |
2026 Q2
0 quarters
|
|
452
Empery Digital
EMPD
$81.4M
| $48.6K | 0.03% |
+13,662
| New | +$61.1K |
2026 Q2
0 quarters
|
|
453
N-able
NABL
$860M
| $46.3K | 0.02% |
+12,615
| New | +$52.5K |
2026 Q2
0 quarters
|
|
454
Geron
GERN
$771M
| $45.5K | 0.02% |
+35,580
| New | +$50.1K |
2026 Q2
0 quarters
|
|
455
SmartRent
SMRT
$220M
| $44.4K | 0.02% |
37,307
-41,174
| -52% | -$52.3K |
2025 Q2
4 quarters
|
|
456
Indonesia Energy Corp
INDO
$38.6M
| $43.9K | 0.02% |
16,035
-1,072
| -6% | -$3.26K |
2024 Q4
6 quarters
|
|
457
Allogene Therapeutics
ALLO
$449M
| $42.1K | 0.02% |
20,249
-24,996
| -55% | -$54.9K |
2025 Q2
4 quarters
|
|
458
Agenus
AGEN
$279M
| $41.1K | 0.02% |
+13,421
| New | +$48.1K |
2026 Q2
0 quarters
|
|
459
DELISTED
Cosan
CSAN
| $40.9K | 0.02% |
+14,193
| New | +$50.3K |
2026 Q2
0 quarters
|
|
460
Altimmune
ALT
$434M
| $40.3K | 0.02% |
+13,264
| New | +$39.6K |
2026 Q2
0 quarters
|
|
461
Coty
COTY
$2.81B
| $39.2K | 0.02% |
+18,163
| New | +$39.2K |
2026 Q2
0 quarters
|
|
462
Cerus
CERS
$447M
| $37.1K | 0.02% |
12,700
-5,795
| -31% | -$14.1K |
2024 Q4
6 quarters
|
|
463
ProKidney
PROK
$291M
| $36.4K | 0.02% |
17,822
+4,126
| +30% | +$7.55K |
2026 Q1
1 quarter
|
|
464
Pulmonx
LUNG
$75.2M
| $35.7K | 0.02% |
27,429
+7,649
| +39% | +$10.5K |
2026 Q1
1 quarter
|
|
465
UWM Holdings
UWMC
$366M
| $35.5K | 0.02% |
+15,500
| New | +$48.2K |
2026 Q2
0 quarters
|
|
466
Fate Therapeutics
FATE
$223M
| $35.4K | 0.02% |
13,122
-5,402
| -29% | -$10K |
2025 Q3
3 quarters
|
|
467
Expensify
EXFY
$225M
| $35.1K | 0.02% |
+19,587
| New | +$22K |
2026 Q2
0 quarters
|
|
468
American Battery Technology Co
ABAT
$207M
| $34.1K | 0.02% |
+12,061
| New | +$38.6K |
2026 Q2
0 quarters
|
|
469
JELD-WEN Holding
JELD
$117M
| $33.6K | 0.02% |
22,427
+8,034
| +56% | +$12.4K |
2026 Q1
1 quarter
|
|
470
Lucid Diagnostics
LUCD
$72.1M
| $32.7K | 0.02% |
30,587
+9,071
| +42% | +$9.8K |
2025 Q4
2 quarters
|
|
471
Village Farms International
VFF
$311M
| $30.5K | 0.02% |
+15,247
| New | +$38.1K |
2026 Q2
0 quarters
|
|
472
Blink Charging
BLNK
$61M
| $29.8K | 0.02% |
46,546
-12,639
| -21% | -$9.15K |
2026 Q1
1 quarter
|
|
473
Akebia Therapeutics
AKBA
$188M
| $28.8K | 0.02% |
+25,295
| New | +$30.1K |
2026 Q2
0 quarters
|
|
474
Cardiff Oncology
CRDF
$68.9M
| $28.6K | 0.02% |
22,018
+10,216
| +87% | +$16.2K |
2025 Q4
2 quarters
|
|
475
Neumora Therapeutics
NMRA
$88.3M
| $28.2K | 0.01% |
+16,596
| New | +$31.6K |
2026 Q2
0 quarters
|
|
Similar funds
EL
BFG
AFP
CCMR
CCC
IC
NI
CFG
R Squared's Q2 2026 Portfolio in Review
As of Q2 2026, R Squared held 725 positions worth $190M, up 4.6% from $182M the previous quarter. Its ten largest holdings account for 14% of the portfolio.
R Squared's Q2 2026 filing shows 248 new, 120 increased, 140 reduced and 216 closed positions. Its largest new stake was Meta Platforms (Facebook): 2,795 shares worth $1.57M. The largest sale was Hologic, an estimated $5.96M.
By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 18% a quarter earlier, followed by Technology and Industrials.
- R Squared's largest Q2 2026 buy was Meta Platforms (Facebook): 2,795 shares worth $1.57M.
- R Squared added most to NVIDIA in Q2 2026, an estimated $3.3M increase.
- R Squared's biggest Q2 2026 reduction was Apple, cutting an estimated $3.04M.
- R Squared fully exited Hologic in Q2 2026, selling an estimated $5.96M.
- R Squared's ten largest holdings make up 14% of its $190M portfolio in Q2 2026.
- R Squared opened 248 new positions and closed 216 in Q2 2026.
- R Squared's portfolio value rose 4.6% quarter-over-quarter to $190M.
Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.